Abstract
Purpose
Androgen replacement therapy is a widely accepted form of treatment worldwide for aging men with late-onset hypogonadism (LOH) syndrome. Urologists have been concerned with the use of androgen supplements due to the possibility of enhancing prostate growth. We performed a systematic review and meta-analysis to assess the effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy.
Methods
A literature review was performed to identify all published randomized placebo-controlled trials (RCT) that used exogenous testosterone combined with 5α-reductase inhibitor therapy for the treatment of hypogonadism. The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated, and a systematic review and meta-analysis were conducted.
Results
Five publications involving a total of 250 patients were used in the analysis, including 4 RCTs that were short-term (≤6 mo) comparisons of testosterone plus a 5α-reductase inhibitor with testosterone plus placebo and 3 RCTs that were long-term (18–36 mo) comparisons of testosterone plus a 5α-reductase inhibitor with testosterone plus placebo. In our meta-analysis, we found that testosterone plus a 5α-reductase inhibitor may slow the progression of prostate growth. For the comparison of short-term testosterone plus 5α-reductase inhibitor treatment with testosterone plus placebo therapy, the prostate-specific antigen (PSA) level (the standardized mean difference (SMD) = −0.24, 95 % confidence interval (CI) = −0.45 to 0.04, p = 0.02)) and the prostate volume (SMD = −1.66, 95 % CI = −4.54 to 1.22, p = 0.26) indicated that, compared with testosterone plus placebo therapy, the testosterone plus 5α-reductase inhibitor may decrease the PSA level. For the comparison of long-term testosterone plus 5α-reductase inhibitor with testosterone plus placebo, the PSA level (SMD = −0.53, 95 % CI = −0.84 to 0.21, p = 0.001) and the prostate volume (SMD = −8.53, 95 % CI = −15.51 to 1.54, p = 0.02) showed that, compared with testosterone plus placebo therapy, the testosterone plus 5α-reductase inhibitor treatment may slow the progression of prostate growth.
Conclusions
Our meta-analysis indicates that the treatment of LOH patients with short-term testosterone plus 5α-reductase inhibitor therapy does not lead to prostate growth; however, this treatment could effectively decrease the PSA level. Additionally, long-term testosterone plus 5α-reductase inhibitor therapy could slow the progression of prostate growth.
Similar content being viewed by others
References
Harman SM, Metter EJ, Tobin JD et al (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 86:724–731
Wu FC, Tajar A, Pye SR et al (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors. J Clin Endocrinol Metab 93:2737–2745
Wang C, Nieschlag E, Swerdloff R et al (2009) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 55:121–130
Morales A, Schulman CC, Tostain J et al (2006) Testosterone deficiency syndrome (TDS) needs to be named appropriately–the importance of accurate terminology. Eur Urol 50:407–409
Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876
Roehrborn CG, Boyle P, Nickel JC et al (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441
Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 57:123–131
Fowler JE Jr, Whitmore WF Jr (1982) Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 49:1373–1377
McConnell JD (1995) Prostatic growth: new insights into hormonal regulation. Br J Urol 76(Suppl 1):5–10
Calof OM, Singh AB, Lee ML et al (2005) Adverse events associated with testosterone supple-mentation of older men. J Gerontol A Biol Sci Med Sci 60:1451–1457
Borst SE, Conover CF, Carter CS et al (2007) Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. Am J Physiol Endocrinol Metab 293:507–514
Aggarwal S, Thareja S, Verma A et al (2010) An overview on 5alpha-reductase inhibitors. Steroids 75:109–153
Gruntmanis U (2012) The role of 5 alpha-reductase inhibition in men receiving testosterone replacement therapy. JAMA 307:968–970
Jadad AR (1998) Randomised controlled trials. BMJ Publishing Group, London
Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions, v.5.1 [updated March 2011]. Cochrane Collaboration Web site. http://www.cochrane-handbook.org/
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Amory JK, Watts NB, Easley KA et al (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510
Vaughan C, Goldstein FC, Tenover JL (2007) Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl 28:875–882
Page ST, Hirano L, Gilchriest J et al (2011) Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 186:191–197
Bhasin S, Travison TG, Storer TW et al (2012) Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 307:931–939
Mostaghel EA, Lin DW, Amory JK et al (2012) Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab 97:2809–2817
Bhasin S, Cunningham GR, Hayes FJ et al (2010) Task force, endocrine society. Tes-tosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559
Griffin JE, Wilson JD (1980) The testis. In: Bondy PK, Rosenberg LE (eds) Metabolic control and disease, 8th edn. WB Saunders, Philadelphia, p 1535
Gormley GJ (1995) Finasteride: a clinical review. Biomed Pharmacother 49:319–324
Roehrborn CG, McConnell JD, Saltzman B et al (2002) Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 42:41
Crawford ED, Wilson SS, McConnell JD et al (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422
Roehrborn CG, McConnell JD, Lieber M et al (1999) Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 53:473
McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
Amory JK, Bush MA, Zhi H et al (2011) Oral testosterone with and without concomitant inhibition of 5alpha-reductase by dutasteride in hypogonadal men for 28 days. J Urol 185:626–632
Rittmaster R, Hahn RG, Ray P et al (2008) Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 72:808
Conflict of interest
The authors had no conflicts of interest to declare in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cui, Y., Zong, H., Yang, C. et al. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis. Int Urol Nephrol 45, 979–987 (2013). https://doi.org/10.1007/s11255-013-0477-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-013-0477-0